Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Penicillin allergy labels may fuel superbugs, study warns

NCT ID NCT07177690

Knowledge-focused Sponsor: University of Leeds Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how having a penicillin allergy record affects treatment and antibiotic resistance in patients hospitalized with COVID-19. Many people labeled as allergic to penicillin are not truly allergic, leading to use of less effective antibiotics that can drive resistance. Researchers will compare outcomes and resistance genes in patients with and without a penicillin allergy label, and see if removing incorrect labels reduces resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could show that removing incorrect penicillin allergy labels reduces antibiotic resistance, leading to better treatment guidelines and fewer treatment failures.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. Results may not apply to all settings, and the sample size is modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

214 people

The number who actually took part.

Started

Nov 2021

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

\- Workstream 1 population: Participants included in the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH) study (ISRCTN66682918) \- Workstream 2 population: Participants will be recruited from patients attending outpatient clinics at Leeds Teaching Hospitals NHS Trust, United Kingdom. \- Workstream 3 population: Participants will be recruited from the population of patients participating in the he Allergy Antibiotics and Microbial Resistance (ALABAMA) trial (NCT04108637).

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Workstream 1 1. Adult (\>16 years) with confirmed COVID-19 (positive PCR test) 2. Admitted to participating NHS Trusts/hospitals between 01/02/2020 to 30/06/2020 * Workstream 2 1. Adult (≥18 years) patients with a penicillin allergy or a matched patients (by age and sex) without a penicillin allergy 2. Received antibiotics in the 24 months prior to recruitment 3. Willing to provide saliva +/- stool samples * Workstream 3 1. Patients enrolled into the ALABAMA trial Exclusion Criteria: * Workstream 1 a. Patients with their allergy status missing will be excluded. * Workstream 2 1. Patients unable to give informed consent or who are unwilling/unable to provide saliva samples 2. Unwilling/unable to provide saliva samples * Workstream 3 1. Patients unable to give informed consent or who are unwilling/unable to provide saliva samples 2. Unwilling/unable to provide saliva samples

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 drug allergy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMR Antimicrobial drug resistance Penicillin allergy

Contacts and locations

Locations

  • Leeds Teaching Hospitals NHS trust

    Leeds, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.